Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Grows By 20.8%

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 57,000 shares, a growth of 20.8% from the February 13th total of 47,200 shares. Based on an average trading volume of 225,700 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.0% of the company’s shares are short sold.

Astellas Pharma Trading Up 0.5 %

Shares of ALPMY stock opened at $10.01 on Thursday. The stock has a market capitalization of $18.11 billion, a PE ratio of -45.50 and a beta of 0.29. Astellas Pharma has a 1-year low of $9.05 and a 1-year high of $13.14. The business has a 50-day moving average of $9.67 and a 200 day moving average of $10.56. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.04 and a quick ratio of 0.80.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. As a group, sell-side analysts anticipate that Astellas Pharma will post 0.42 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.